{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:50:27Z","timestamp":1791859827267,"version":"4.3.4"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,12]],"date-time":"2019-05-12T00:00:00Z","timestamp":1557619200000},"content-version":"am","delay-in-days":345,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R15HL103431"],"award-info":[{"award-number":["R15HL103431"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01HL114677"],"award-info":[{"award-number":["R01HL114677"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["R24HL123767"],"award-info":[{"award-number":["R24HL123767"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cardiovascular Medical Research and Education Fund"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.jconrel.2018.04.049","type":"journal-article","created":{"date-parts":[[2018,4,30]],"date-time":"2018-04-30T14:44:09Z","timestamp":1525099449000},"page":"113-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Repurposing rosiglitazone, a PPAR-\u03b3 agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH"],"prefix":"10.1016","volume":"280","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1769-4067","authenticated-orcid":false,"given":"Jahidur","family":"Rashid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Alobaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taslim A.","family":"Al-Hilal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Hammouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan F.","family":"McMurtry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Nozik-Grayck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt R.","family":"Stenmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fakhrul","family":"Ahsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2018.04.049_bb0005","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1753465809369619","article-title":"PPARgamma as a potential therapeutic target in pulmonary hypertension","volume":"4","author":"Sutliff","year":"2010","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0010","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1161\/01.RES.0000073585.50092.14","article-title":"Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth","volume":"92","author":"Ameshima","year":"2003","journal-title":"Circ. Res."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1126\/scitranslmed.3000267","article-title":"PPARgamma activation: a potential treatment for pulmonary hypertension","volume":"1","author":"Hansmann","year":"2009","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1152\/physiolgenomics.00094.2009","article-title":"Effect of PPARgamma inhibition on pulmonary endothelial cell gene expression: gene profiling in pulmonary hypertension","volume":"40","author":"Tian","year":"2009","journal-title":"Physiol. Genomics"},{"key":"10.1016\/j.jconrel.2018.04.049_bb0025","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ccm.2013.08.010","article-title":"Epidemiology of pulmonary arterial hypertension","volume":"34","author":"Taichman","year":"2013","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0030","first-page":"L559","article-title":"PPAR{gamma} regulates hypoxia-induced Nox4 expression in human pulmonary artery smooth muscle cells through NF-{kappa}B","volume":"299","author":"Lu","year":"2010","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0035","series-title":"Avandia Prescribing Information","author":"USFDA","year":"2014"},{"key":"10.1016\/j.jconrel.2018.04.049_bb0040","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/MLR.0000000000000502","article-title":"Disparities in discontinuing rosiglitazone following the 2007 FDA safety alert","volume":"54","author":"Qato","year":"2016","journal-title":"Med. Care"},{"key":"10.1016\/j.jconrel.2018.04.049_bb0045","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1172\/JCI32503","article-title":"An antiproliferative BMP-2\/PPARgamma\/apoE axis in human and murine SMCs and its role in pulmonary hypertension","volume":"118","author":"Hansmann","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133391","article-title":"PPARgamma ligands attenuate hypoxia-induced proliferation in human pulmonary artery smooth muscle cells through modulation of MicroRNA-21","volume":"10","author":"Green","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2018.04.049_bb0055","first-page":"283","article-title":"Effects of peroxisome proliferator-activated receptor gamma ligands on monocrotaline-induced pulmonary hypertension in rats","volume":"43","author":"Matsuda","year":"2005","journal-title":"Nihon Kokyuki Gakkai Zasshi"},{"key":"10.1016\/j.jconrel.2018.04.049_bb0060","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1165\/rcmb.2008-0132OC","article-title":"Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model","volume":"42","author":"Nisbet","year":"2010","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0065","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3892\/br.2015.465","article-title":"Activation of peroxisome proliferator-activated receptor gamma ameliorates monocrotaline-induced pulmonary arterial hypertension in rats","volume":"3","author":"Xie","year":"2015","journal-title":"Biomed. Rep."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0070","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1161\/CIRCULATIONAHA.109.927681","article-title":"Formation of plexiform lesions in experimental severe pulmonary arterial hypertension","volume":"121","author":"Abe","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jconrel.2018.04.049_bb0075","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM199507273330403","article-title":"Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension","volume":"333","author":"Giaid","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0080","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of endothelin-1 in the lungs of patients with pulmonary hypertension","volume":"328","author":"Giaid","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0085","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jconrel.2017.02.003","article-title":"Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH)","volume":"250","author":"Rashid","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.04.049_bb0090","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jconrel.2008.03.013","article-title":"Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation","volume":"128","author":"Rawat","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.04.049_bb0095","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijpharm.2013.07.043","article-title":"Risk based approach for design and optimization of stomach specific delivery of rifampicin","volume":"455","author":"Vora","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0100","first-page":"447","article-title":"Simulants of lung interstitial fluid","volume":"36","author":"Moss","year":"1979","journal-title":"Health Phys."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0105","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1002\/jps.21946","article-title":"Feasibility study of aerosolized prostaglandin E1 microspheres as a noninvasive therapy for pulmonary arterial hypertension","volume":"99","author":"Gupta","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0110","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1016\/j.febslet.2006.06.034","article-title":"Tumor necrosis factor-alpha and interleukin-1beta increases CTRP1 expression in adipose tissue","volume":"580","author":"Kim","year":"2006","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0115","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jpba.2016.06.022","article-title":"A highly sensitive LC-MS\/MS method for concurrent determination of sildenafil and rosiglitazone in rat plasma","volume":"129","author":"Rashid","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0120","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1096\/fj.00-0343com","article-title":"Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension","volume":"15","author":"Taraseviciene-Stewart","year":"2001","journal-title":"FASEB J."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0125","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/01.RES.0000261658.12024.18","article-title":"Rho kinase\u2013mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats","volume":"100","author":"Oka","year":"2007","journal-title":"Circ. Res."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0130","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jconrel.2013.01.011","article-title":"Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension","volume":"167","author":"Gupta","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.04.049_bb0135","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ijpharm.2008.04.042","article-title":"Principles of encapsulating hydrophobic drugs in PLA\/PLGA microparticles","volume":"364","author":"Wischke","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0140","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0168-3659(01)00373-X","article-title":"POE\u2013PEG\u2013POE triblock copolymeric microspheres containing protein: I. Preparation and characterization","volume":"75","author":"Yang","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.04.049_bb0145","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ejpb.2008.01.013","article-title":"Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency","volume":"69","author":"Song","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0150","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ijpharm.2007.08.034","article-title":"PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: systematic study of particle size and drug entrapment efficiency","volume":"350","author":"Song","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0155","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/162962","article-title":"A fractional factorial design to study the effect of process variables on the preparation of hyaluronidase loaded plga nanoparticles","volume":"2014","author":"Narayanan","year":"2014","journal-title":"Enzyme Res."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0160","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.biomaterials.2008.12.044","article-title":"Development of highly porous large PLGA microparticles for pulmonary drug delivery","volume":"30","author":"Yang","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2018.04.049_bb0165","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1477-044X-5-2","article-title":"Process and formulation variables in the preparation of injectable and biodegradable magnetic microspheres","volume":"5","author":"Zhao","year":"2007","journal-title":"Biomagn. Res. Technol."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0170","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0168-3659(96)01475-7","article-title":"Protein-loaded poly (dl-lactide-co-glycolide) microparticles for oral administration: formulation, structural and release characteristics","volume":"43","author":"Rafati","year":"1997","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.04.049_bb0175","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/02652040010000474","article-title":"Preparation and characterization of hCG-loaded polylactide or poly (lactide-co-glycolide) microspheres using a modified water-in-oil-in-water (w\/o\/w) emulsion solvent evaporation technique","volume":"18","author":"Zhu","year":"2001","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0180","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0168-3659(95)00010-6","article-title":"Preparation of porous and nonporous biodegradable polymeric hollow microspheres","volume":"35","author":"Crotts","year":"1995","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.04.049_bb0185","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jconrel.2012.07.003","article-title":"PEG-PLGA based large porous particles for pulmonary delivery of a highly soluble drug, low molecular weight heparin","volume":"162","author":"Patel","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.04.049_bb0190","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrd2153","article-title":"Inhaling medicines: delivering drugs to the body through the lungs","volume":"6","author":"Patton","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0195","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jconrel.2013.06.012","article-title":"Rosiglitazone-loaded nanospheres for modulating macrophage-specific inflammation in obesity","volume":"170","author":"Di Mascolo","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.04.049_bb0200","first-page":"L885","article-title":"Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling","volume":"292","author":"Crossno","year":"2007","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118650","article-title":"Circulating level of CTRP1 in patients with nonalcoholic fatty liver disease (NAFLD): is it through insulin resistance?","volume":"10","author":"Shabani","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2018.04.049_bb0210","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1440-1843.2010.01756.x","article-title":"Rosiglitazone attenuates hypoxia-induced pulmonary arterial hypertension in rats","volume":"15","author":"Kim","year":"2010","journal-title":"Respirology"},{"key":"10.1016\/j.jconrel.2018.04.049_bb0215","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1161\/CIRCRESAHA.107.148015","article-title":"Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature","volume":"101","author":"Mittal","year":"2007","journal-title":"Circ. Res."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0220","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/j.2040-4603.2011.tb00329.x","article-title":"Smooth muscle cell hypertrophy, proliferation, migration and apoptosis in pulmonary hypertension","volume":"1","author":"Tajsic","year":"2011","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0225","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.1016\/j.jacc.2004.02.029","article-title":"Cellular and molecular pathobiology of pulmonary arterial hypertension","volume":"43","author":"Humbert","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0230","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1046\/j.1365-2125.2003.01892.x","article-title":"Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications","volume":"56","author":"Labiris","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0235","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/jps.2600750502","article-title":"Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation","volume":"75","author":"Byron","year":"1986","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0240","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0021-8502(86)90035-2","article-title":"Deposition of particles in the human respiratory tract in the size range 0.005\u201315\u202f\u03bcm","volume":"17","author":"Heyder","year":"1986","journal-title":"J. Aerosol Sci."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0245","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: an overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.04.049_bb0250","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1081\/PDT-100100543","article-title":"Enhancing initial release of peptide from poly(d,l-lactide-co-glycolide) (PLGA) microspheres by addition of a porosigen and increasing drug load","volume":"5","author":"Ravivarapu","year":"2000","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0255","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ijpharm.2009.12.040","article-title":"Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett-Burman design","volume":"389","author":"Rahman","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0260","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijbiomac.2015.12.069","article-title":"Development of zolmitriptan loaded PLGA\/poloxamer nanoparticles for migraine using quality by design approach","volume":"85","author":"Girotra","year":"2016","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0265","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.pharmthera.2017.04.003","article-title":"Inhaled efficacious dose translation from rodent to human: a retrospective analysis of clinical standards for respiratory diseases","volume":"178","author":"Phillips","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0270","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1126\/science.276.5320.1868","article-title":"Large porous particles for pulmonary drug delivery","volume":"276","author":"Edwards","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2018.04.049_bb0275","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1042\/BJ20081240","article-title":"Molecular, biochemical and functional characterizations of C1q\/TNF family members: adipose-tissue-selective expression patterns, regulation by PPAR-gamma agonist, cysteine-mediated oligomerizations, combinatorial associations and metabolic functions","volume":"416","author":"Wong","year":"2008","journal-title":"Biochem. J."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0280","series-title":"Diagnosis and Treatment of Pulmonary Hypertension","first-page":"139","article-title":"Targeting the NO-sGC-cGMP pathway in pulmonary arterial hypertension","author":"Watanabe","year":"2017"},{"key":"10.1016\/j.jconrel.2018.04.049_bb0285","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/1753465816665289","article-title":"A review of therapeutic agents for the management of pulmonary arterial hypertension","volume":"11","author":"Hahn","year":"2017","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0290","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4103\/2045-8932.109911","article-title":"Nitric oxide deficiency in pulmonary hypertension: pathobiology and implications for therapy","volume":"3","author":"Tonelli","year":"2013","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0295","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1074\/jbc.M109.067868","article-title":"Hypoxic repression of endothelial nitric-oxide synthase transcription is coupled with eviction of promoter histones","volume":"285","author":"Fish","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0300","first-page":"H1921","article-title":"Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms","volume":"267","author":"McQuillan","year":"1994","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0305","doi-asserted-by":"crossref","first-page":"518","DOI":"10.2310\/JIM.0b013e318165e921","article-title":"The role of PPARgamma in pulmonary vascular disease","volume":"56","author":"Hart","year":"2008","journal-title":"J. Investig. Med."},{"key":"10.1016\/j.jconrel.2018.04.049_bb0310","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/thx.2004.031724","article-title":"The endothelin system and its role in pulmonary arterial hypertension (PAH)","volume":"60","author":"Pepke-Zaba","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.jconrel.2018.04.049_bb0315","first-page":"L881","article-title":"The PPARgamma ligand rosiglitazone attenuates hypoxia-induced endothelin signaling in vitro and in vivo","volume":"301","author":"Kang","year":"2011","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918302499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918302499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:34:59Z","timestamp":1759160099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365918302499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":63,"alternative-id":["S0168365918302499"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.04.049","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing rosiglitazone, a PPAR-\u03b3 agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.04.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}